Casdin Capital, LLC → Standard BioTools Inc. LAB

Item 4 of the Schedule 13D amendment filed on November 28, 2025 is hereby supplemented by the addition of the following: On June 6, 2026, the Issuer, Treeline Biosciences, Inc., a Delaware corporation (the "Company"), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "Merger"). Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger ("Effective Time"), each share of capital stock of the Company will be converted into the right to receive a number of Shares in accordance with the Exchange Ratio (as defined in the Merger Agreement). Voting Agreement Also on June 6, 2026, in connection with the Merger Agreement, the Issuer, the Company and Merger Sub entered into a voting agreement (the "Voting Agreement") with Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund, L.P., Casdin Partners Master Fund, L.P. and Eli Casdin (collectively, the "Casdin Parties"). Pursuant to the Voting Agreement, the Casdin Parties have agreed, among other things, subject to the terms and conditions thereof, to: (i) vote their owned securities of record of the Issuer: (1) in favor of the approval of (i) the issuance of Shares to holders of Company stock pursuant to the Merger Agreement, (ii) an amendment to the Issuer's charter pursuant to which the name of Issuer will be changed to "Treeline Biosciences Holdings, Inc.", (iii) a reverse stock split of all outstanding Shares at a reverse stock split ratio mutually agreed to by the Company and the Issuer, and (iv) the adoption of the Post-Closing Equity Incentive Plan and Post-Closing ESPP (each as defined in the Merger Agreement); (2) in favor of any proposal to adjourn to a later date if there is not a quorum or sufficient affirmative votes (in person or by proxy) for approval of any such matters on the date on which the meeting is held; (3) against any action or agreement that would reasonably be expected to result in the conditions set forth in the Merger Agreement not being fulfilled or a breach of a covenant, representation or warranty or any other material obligation or agreement of the Issuer contained in the Merger Agreement; (4) against any action, proposal, transaction or agreement that would reasonably be expected to prevent or materially delay the consummation of the transactions contemplated by the Merger Agreement or the fulfillment of the Issuer's or Merger Sub's conditions to closing under the Merger Agreement; and (5) against any third party acquisition transactions; and (ii) comply with certain restrictions on the disposition of such shares, in each case subject to the terms and conditions contained therein. In the event that the Special Committee of the Issuer's board of directors effects a Parent Change in Recommendation (as defined in the Merger Agreement): (i) 37.5% of the Casdin Parties' shares of Issuer capital stock entitled to vote with respect to a matter that is the subject of Parent Change in Recommendation (an "Applicable Matter") are released from the voting requirements and may be voted in the Casdin Parties' discretion; and (ii) if, the aggregate covered shares subject to voting requirements under the Voting Agreement and any covered shares subject to similar voting agreements entered into with other stockholders of the Issuer in connection with the Merger Agreement represent more than 30% of the outstanding shares of Issuer capital stock entitled to vote on the Applicable Matter, then a number of shares will be released on a pro rata basis (across all such stockholders) such that the aggregate number of outstanding shares of Issuer capital stock subject to the voting requirements in the Voting Agreement and all other voting agreements is reduced to approximately 30% of the outstanding shares of Issuer capital stock. The Voting Agreement further provides that nothing therein restricts any stockholder (or its affiliates or designees) who serves as a director, board observer or officer of Parent from acting or voting in such capacity in accordance with his or her fiduciary duties. Actions taken in such capacity, including supporting or advocating for a change in recommendation or a superior proposal, will not constitute a breach of the Voting Agreement, which applies solely to such person in his, her or its capacity as a stockholder. The foregoing description of the Voting Agreement does not purport to be complete and is qualified in its entirety by reference to the form of the Voting Agreement, which is filed as an exhibit to